Login / Signup

Real-life data on efficacy and safety of original Adalimumab and biosimilar Adalimumab (ABP 501) in pediatric rheumatic diseases.

Kadir UluMustafa ÇakanŞengül ÇağlayanRamazan Emre YiğitFerhat DemirTaner CoşkunerEsra KardeşBetul Sozeri
Published in: Expert opinion on biological therapy (2022)
There was no significant difference between the biosimilar and the original product in efficacy and safety.
Keyphrases
  • rheumatoid arthritis
  • juvenile idiopathic arthritis
  • hidradenitis suppurativa
  • ulcerative colitis
  • electronic health record
  • disease activity
  • young adults
  • deep learning
  • childhood cancer